Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
Partner
Pirozzolo, Jack W.
Partner

Related Blogs

Capabilities

Suggested News & Insights

DOJ Announces Second Settlement Resolving FCA Allegations Based on Employment DiscriminationAugust 28, 2026
Original Source
Second Circuit Clarifies Scope of “Property” that an FCA “Claim” May SeekAugust 17, 2026
Original Source
DOJ’s $5.15 Million FCA Settlement Reinforces Focus on Tariff and Customs ComplianceAugust 11, 2026
Original Source
$14.1 Million FCA Settlement Underscores Medicare Advantage Coding ScrutinyAugust 6, 2026
Original Source
New York Ethics Opinion Addresses Ethical Limits on Attorney Participation in Whistleblower InvestigationsJuly 30, 2026
Original Source
Laboratory, Owners, and Investors Settle COVID-19 Testing Fraud Allegations for $24 MillionJuly 27, 2026
Original Source